Cardiac amyloidosis: an emerging target in HFpEF?10' education - July 19, 2019 - Prof. van der Meer, MD, PhD - Groningen, The Netherlands
Video navigation menu
- A patient case: a 74-year old male with sudden shortness of breath 0:29
- Additional diagnostic test: bone scintigraphy and more 3:49
- Diagnosis: HFpEF based on wild-type aTTR amyloidosis 5:11
- Treatment options for ATTR amyolidosis 6:48
This lecture by prof. van der Meer was part of a CME accredited symposium "Reshaping the future of heart failure management - Translating innovations to practice in HFpEF".
Prof. van der Meer received both this MD and PhD cum laude from the University of Groningen in the Netherlands and worked as a visiting scientist at Harvard Medical School, Boston, MA, USA. He is a cardiologist and director of the coronary care unit at the UMCG, Groningen, The Netherlands. His research-group consists of PhD students and post-docs with various backgrounds working on (translational) research topics.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by unrestricted educational grants from Novartis, Novo Nordisk and Pfizer.